

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Obeticholic acid for treating primary biliary cirrhosis**

**Batch 43**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

- 1) The scoping workshop attendees noted that because of the rare nature of the disease it is essential that patients have the same opportunity to receive new therapies.
- 2) It was noted that because of the associated negative connotations of cirrhosis, people with primary biliary cirrhosis face stigma in society.
- 3) They also noted that primary biliary cirrhosis is more common in women. It was acknowledged that the Committee will not make separate recommendations on the basis of sex, and consultees clarified that the point was raised to ensure women are represented during the appraisal of obeticholic acid for primary biliary cirrhosis.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

In relation to the equalities issues raised, the Committee's recommendations are unlikely to exclude any group of people from consideration, to lead to recommendations that have a different impact on people protected by the equalities legislation than the wider population or have an adverse impact on people with disabilities. As part of its deliberations, the Committee will consider the stigma and negative associations of cirrhosis.

As part of its process, NICE invites all relevant stakeholder organisations to participate in the appraisal and this includes patient groups that are expected to represent all patients with PBC.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made to the scope to highlight any potential equality issue.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equality issues have been identified during the scoping process.

**Approved by Associate Director (name):** Janet Robertson

**Date:** 01.08.2016